Professional Drone LiDAR and Drone Photogrammetry More Accessible and Affordable Than Ever Before: Microdrones as a Service (mdaaS) Available Now

Rome, NY- Microdrones announces the launch of mdaaS- Microdrones as a Service, making its survey equipment and solutions accessible to an even broader market of surveyors and geomatics professionals. MdaaS introduces drone surveying solutions, including everything needed to do drone LiDAR and surveying the right way, with convenient hardware and software packages and affordable monthly payment options as low as $1,042 USD.

Microdrones CEO, Vivien Heriard-Dubreuil explains, “We developed mdaaS to propel the industry and expand the market from innovators and early adopters into the early majority phase of growth. The demand and interest are obvious; this new business model makes the adoption decision easy for a broader addressable market. More companies will be able to afford this technology, when offered as a monthly subscription, as compared to the traditional model of purchasing survey equipment in one lump sum.”

Surveying and geomatics professionals will be able to configure and optimize their survey equipment, service and software selections according to business needs and anticipated usage. “The decision-making process is much easier, as it pertains to selecting a system,” explains Heriard-Dubreuil. “For example, one single mdMappper1000DG aaS system can collect data, and the user can decide to process its data in DG or PPK depending on the job. With the mdLiDAR1000 aaS system, you have now access to many more data processing modules, including strip adjustment, precision enhancement, point colorization and more.”

Post processing specifications are selectable in Microdrones proprietary mdInfinity data processing software, so that expense can be matched on a project-by-project basis to the data deliverable demands of the client. According to Heriard-Dubreuil, “Our mdInfinity software provides us with the platform to continuously build our data science depth and library of applications; we will grow with our customers and the breadth of projects they tackle.”

Microdrones customers start by deciding which system(s) meet their overall needs, selecting from the mdLiDAR, mdMapper and mdTector families of fully integrated technology. Vice President of Global Sales for Microdrones, Vincent Legrand, explains, “After selecting survey equipment, the user decides whether they prefer to buy their equipment in one lump sum or to use our subscription model with convenient monthly payments. Data post processing choices are also flexible; our mdInfinity software allows users to Pay Per Project, or to purchase an Unlimited Plan.”

Vice President of Global Marketing for Microdrones, Mike Dziok, adds, “We meet the customer where they want to be, in terms of options, choices, payment plans, and their preferences for maintenance, service, training and support. What we’re really doing is making it easier for more surveyors to adopt this technology, via reasonably priced options in a subscription model. They can start enjoying the benefits right away.”

Sales professionals from Microdrones have been very responsive to the early buzz and high level of inquiries.  “Our sales teams are well trained to explain the full suite of options and to help customers maximize their decision,” said Legrand. “Given the higher inquiry volume, it may take a day or two, but our team is working all hours and getting back to everyone; the interest level is very exciting.”

In addition to new web pages and a helpful sales team, on on Wednesday, May 13th, 9:00AM EST or 6:00PM EST Microdrones is offering an educational webinar, “mdaaS: An easy way to Make Drone LiDAR and Drone Surveying a Part of Your Business.” The webinar will help customers understand their options within the program, and to configure what might be best for them. Participants will be able to take advantage of a special offer to receive a voucher for up to $3000 to be used towards the purchase of Microdrones mdaaS related products and services. To register, visit this link and complete the easy form.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More